FDA Authorizes Additional COVID-19 Vaccine
July 13, 2022
Xalkori Granted New Indication to Treat Non-Cancerous Tumors
July 14, 2022
July 14, 2022 – Diacomit® (stiripentol) is now indicated for use with clobazam to treat seizures associated with Dravet syndrome in patients at least six months of age and weighing at least 7kg (15.4 pounds).
- First FDA approved in 2018, Diacomit was originally indicated only for use in patients at least two years of age.
- Recommended daily dosing is 50mg/kg of the patient’s weight, divided into two to three doses and taken by mouth with water during a meal. For patients who weigh less than 10kg (22 pounds), dosing frequency should not exceed twice daily. For all patients, daily dosing should not exceed 3,000mg.